Business · 12/10/2017

FDA Announces Draft Guidance for Developing Antiviral Drugs Against Respiratory Syncytial Virus Infection

The FDA has released a draft guidance to help pharmaceutical companies develop antiviral drugs for the prevention and treatment of RSV infections, a common cause of respiratory illness in infants and vulnerable populations.